Platelet transfusion: basic aspects

被引:19
作者
Holbro, Andreas [1 ]
Infanti, Laura [1 ]
Sigle, Joerg [2 ]
Buser, Andreas [1 ]
机构
[1] Swiss Red Cross, Ctr Blood Transfus, CH-4031 Basel, Switzerland
[2] Swiss Red Cross, Ctr Blood Transfus, Aarau, Switzerland
关键词
platelets; transfusion; refractoriness; safety; MOLECULARLY BASED ALGORITHM; PATHOGEN-INACTIVATION; WHOLE-BLOOD; THERAPEUTIC-EFFICACY; HISTOCOMPATIBILITY DETERMINATION; ADDITIVE SOLUTION; IN-VITRO; APHERESIS; PLASMA; SAFETY;
D O I
10.4414/smw.2013.13885
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Platelet transfusions have been shown to prevent major haemorrhage and improve survival in thrombocytopenic patients. Since then, advances in the preparation of platelet components, including the introduction of pathogen reduction techniques, have been achieved. The number of transfused platelet components is still growing owing to the increasing number of patients treated for haemato-oncological diseases. Additionally, indications have been extended, for example to patients with drug-induced platelet dysfunction. This review focuses on current platelet component production and storage techniques, including pathogen reduction, indications for platelet transfusion and safety issues including alloimmunisation and management of platelet refractoriness.
引用
收藏
页数:10
相关论文
共 86 条
[1]  
ANDERSON KC, 1990, NEW ENGL J MED, V323, P315
[2]  
Blundell J, 1818, Med Chir Trans, V9, P56
[3]   Bacterial contamination of blood components [J].
Brecher, ME ;
Hay, SN .
CLINICAL MICROBIOLOGY REVIEWS, 2005, 18 (01) :195-+
[4]   A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology [J].
Cazenave, J. -P ;
Follea, G. ;
Bardiaux, L. ;
Boiron, J. -M. ;
Lafeuillade, B. ;
Debost, M. ;
Lioure, B. ;
Harousseau, J. -L. ;
Tabrizi, R. ;
Cahn, J. -Y ;
Michallet, M. ;
Ambruso, D. ;
Schots, R. ;
Tissot, J. -D. ;
Sensebe, L. ;
Kondo, T. ;
McCullough, J. ;
Rebulla, P. ;
Escolar, G. ;
Mintz, P. ;
Heddle, N. M. ;
Goodrich, R. P. ;
Bruhwyler, J. ;
Le, C. ;
Cook, R. J. ;
Stouch, B. .
TRANSFUSION, 2010, 50 (11) :2362-2375
[5]   How I manage neonatal thrombocytopenia [J].
Chakravorty, Subarna ;
Roberts, Irene .
BRITISH JOURNAL OF HAEMATOLOGY, 2012, 156 (02) :155-162
[6]   Considerations in the selection of a platelet component: Apheresis versus whole blood-derived [J].
Chambers, LA ;
Herman, JH .
TRANSFUSION MEDICINE REVIEWS, 1999, 13 (04) :311-322
[7]   Preclinical safety profile of plasma prepared using the INTERCEPT Blood System [J].
Ciaravino, V ;
McCullough, T ;
Cimino, G ;
Sullivan, T .
VOX SANGUINIS, 2003, 85 (03) :171-182
[8]   The role of toxicology assessment in transfusion medicine [J].
Ciaravino, V ;
McCullough, T ;
Cimino, G .
TRANSFUSION, 2003, 43 (10) :1481-1492
[9]  
Cid J, 2005, TRANSFUSION, V45, P453, DOI 10.1111/j.1537-2995.2005.00440.x
[10]   Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta-analysis of randomized controlled trials [J].
Cid, J. ;
Escolar, G. ;
Lozano, M. .
VOX SANGUINIS, 2012, 103 (04) :322-330